Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cellectis
Biotech
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
Cellectis kicked off 2026 promising “huge momentum” for its allogeneic CAR-Ts, but the biotech was unable to resist the dominance of in vivo options.
James Waldron
Sep 14, 2026 5:26am
Allogeneic CAR-T biotechs fight to escape 'nuclear winter'
Feb 11, 2026 11:00am
Cellectis drops one of its 3 clinical-stage CAR-Ts
Nov 5, 2024 7:15am
AstraZeneca takes 22% stake in Cellectis under 10-asset collab
Nov 1, 2023 8:45am
Cellectis culls CAR-T over cost of kick-starting slow trial
May 5, 2023 8:20am
Mayo Clinic cell and gene therapy accelerator launches startup
Jan 3, 2023 9:50am
